These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9198166)

  • 1. Current status of activation markers in ischemic heart disease: markers of coagulation activation.
    Merlini PA; Ardissino D
    Thromb Haemost; 1997 Jul; 78(1):276-9. PubMed ID: 9198166
    [No Abstract]   [Full Text] [Related]  

  • 2. Is fibrinolysis critical for acute coronary syndromes?
    Kluft C; Andreotti F
    Ital Heart J; 2001 Sep; 2(9):639-40. PubMed ID: 11666088
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antithrombotic therapy in acute coronary syndrome].
    Chazov EI; Panchenko EP
    Ter Arkh; 2000; 72(3):65-75. PubMed ID: 10776658
    [No Abstract]   [Full Text] [Related]  

  • 4. [Platelet activation in acute coronary syndrome and interventional therapy].
    Bigalke B; Lindemann S; Gawaz M
    Hamostaseologie; 2007 Dec; 27(5):338-43. PubMed ID: 18060243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute coronary syndromes: new developments in pharmacological treatment strategies.
    Gylys K; Gold M
    Crit Care Nurse; 2000 Apr; Suppl():3-14; quiz 15-6. PubMed ID: 11876169
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet activation in myocardial ischemic syndromes.
    Gurbel PA; Bliden KP; Hayes KM; Tantry U
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):535-45. PubMed ID: 15225113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
    Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coagulation spectrum in coronary sclerosis and infarct].
    Rex J
    Z Gesamte Inn Med; 1968 Apr; 23(7):Suppl:97-8. PubMed ID: 4177687
    [No Abstract]   [Full Text] [Related]  

  • 9. Markers of activated coagulation in acute coronary syndromes.
    Goetze JP
    J Am Coll Cardiol; 2008 Jun; 51(25):2430-1. PubMed ID: 18565401
    [No Abstract]   [Full Text] [Related]  

  • 10. Ischemic heart disease (coronary thrombolysis).
    Kanmatsuse K; Nagao K; Kikushima K; Shioiri K
    Intern Med; 1998 Feb; 37(2):203-5. PubMed ID: 9550610
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effect of the duration of coronary occlusion on the healing of an experimental myocardial infarct].
    Syroïd DV; Sokrut VM; Shvyrenko IR
    Fiziol Zh (1994); 1999; 45(6):26-30. PubMed ID: 10687078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
    Mälarstig A; Lindahl B; Wallentin L; Siegbahn A
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1667-73. PubMed ID: 16627810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current principles of thrombolytic therapy of acute coronary syndrome without ST elevation].
    Dudka PF; Il'nyts'kyĭ PI; Lukasevych LM; Ktitareva VI; Mykhaĭlevs'ka TV
    Lik Sprava; 2004; (3-4):15-20. PubMed ID: 15318818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
    Oldgren J; Siegbahn A; Grip L; Linder R; Thygesen K; Wallentin L
    Thromb Haemost; 2004 Feb; 91(2):381-7. PubMed ID: 14961168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the optimal medical management of ischemic heart failure?
    Cleland JG; Alamgir F; Nikitin NP; Clark AL; Norell M
    Prog Cardiovasc Dis; 2001; 43(5):433-55. PubMed ID: 11251129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The year in non-ST-segment elevation acute coronary syndrome.
    Giugliano RP; Braunwald E
    J Am Coll Cardiol; 2007 Oct; 50(14):1386-95. PubMed ID: 17903640
    [No Abstract]   [Full Text] [Related]  

  • 17. Coagulation factors, activation markers and risk of coronary heart disease: the Northwick Park Heart Studies.
    Lowe GD
    J Thromb Haemost; 2008 Feb; 6(2):256-8. PubMed ID: 18021300
    [No Abstract]   [Full Text] [Related]  

  • 18. Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease.
    Califf RM; Mark DB
    Am Heart J; 1997 Nov; 134(5 Pt 2):S88-96. PubMed ID: 9396640
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: basal state and effect of successful dilation.
    Lehmann KG; Gonzales E; Tri BD; Vaziri ND
    Am Heart J; 1999 Feb; 137(2):274-83. PubMed ID: 9924161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood.
    Kalweit G; Bach J; Huwer H; Winning J; Hellstern P
    Thromb Res; 2005; 116(1):33-9. PubMed ID: 15850606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.